Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

BlossomHill Therapeutics, Inc.

NASDAQ: BLSM · Life Sciences · 4 alerts · CIK 1839970

Share price
$13.65Close, Nov 16
Market cap
$434M
Shares outstanding
31.78MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BlossomHill Therapeutics, Inc. filings on SEC EDGAR ↗

4:31 PM ET 10-Q
Financial Results

BlossomHill Therapeutics Q3 2026 Results: Net Loss of $24M, Loss Widens

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company with two product candidates, BH-30643 and BH-30236, in early clinical development and one preclinical candidate, BH-501284. The company has incurred substantial losses since inception and anticipates continued losses as it advances its precision medicine programs for genetically defined cancers.

Key figure
Net loss $24M
4:16 PM ET 8-K
Financial Results

BlossomHill Therapeutics Financial Results

BlossomHill Therapeutics reported third quarter 2026 financial results, ending the period with $224.9 million in cash and cash equivalents. The company aligned with the FDA on a Phase 2 dose for BH-30643 and plans to initiate the pivotal SOLARA-2 trial in Q1 2027 for patients with EGFR C797S-positive NSCLC.

Term
Q3 2026

“We are pleased to have aligned with the FDA on a recommended Phase 2 dose of 50 mg BID based on favorable PK, safety and efficacy data in the Phase 1 portion of the SOLARA trial. We are now preparing to initiate SOLARA-2, a single arm, pivotal Phase 2 trial designed to evaluate BH-30643 in both chemotherapy-naive and chemotherapy-pretreated patients with C797S-positive NSCLC after progression on a third-generation EGFR TKI.”

J. Jean Cui, Ph.D., Founder, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.